Literature DB >> 17137291

Physical interaction of two cancer-testis antigens, MAGE-C1 (CT7) and NY-ESO-1 (CT6).

Hearn J Cho1, Otavia L Caballero, Sacha Gnjatic, Valéria C C Andrade, Gisele W Colleoni, Andre L Vettore, Hasina H Outtz, Sheila Fortunato, Nasser Altorki, Cathy A Ferrera, Ramon Chua, Achim A Jungbluth, Yao-Tseng Chen, Lloyd J Old, Andrew J G Simpson.   

Abstract

Cancer/testis (CT) antigens are the protein products of germ line-associated genes that are activated in a wide variety of tumors and can elicit autologous cellular and humoral immune responses. CT antigens can be divided between those that are encoded on the X chromosome (CT-X antigens) and those that are not (non-X CT antigens). Among the CT-X antigens, the melanoma antigen gene (MAGE) family, defined by a shared MAGE homology domain (MHD), is the largest. CT-X genes are frequently expressed in a coordinate manner in cancer cells, and their expression appears to be modulated by epigenetic mechanisms. The expression of CT-X genes is associated with advanced disease and poor outcome in different tumor types. We used the yeast two-hybrid system to identify putative MHD-interacting proteins. The MHD of MAGE-C1 (CT7) was used as bait to screen a human testis cDNA library. This study identified NY-ESO-1 (CT6) as a MAGE-C1 binding partner. Immunoprecipitation and immunofluorescence staining confirmed MAGE-C1 interaction with NY-ESO-1, and cytoplasmic co-localization of both proteins in melanoma cells. Co-expression of these two genes was found to occur in cancer cell lines from different origins, as well as in primary tumors (multiple myeloma and non-small cell lung cancer samples). This is the first report of direct interaction between two CT antigens and may be pertinent in the light of the frequently coordinated expression of these proteins.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17137291

Source DB:  PubMed          Journal:  Cancer Immun        ISSN: 1424-9634


  20 in total

1.  Cancer/testis antigens as molecular drug targets using network pharmacology.

Authors:  Anuj Kumar; Drista Sharma; M L Aggarwal; K M Chacko; Tarun Kumar Bhatt
Journal:  Tumour Biol       Date:  2016-10-05

2.  Expression of cancer-testis antigen in multiple myeloma.

Authors:  Li He; Jing-Na Ji; Shang-Qin Liu; Er Xue; Qing Liang; Zi Ma
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2014-04-08

3.  Cancer-testis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells.

Authors:  Djordje Atanackovic; York Hildebrandt; Adam Jadczak; Yanran Cao; Tim Luetkens; Sabrina Meyer; Sebastian Kobold; Katrin Bartels; Caroline Pabst; Nesrine Lajmi; Maja Gordic; Tanja Stahl; Axel R Zander; Carsten Bokemeyer; Nicolaus Kröger
Journal:  Haematologica       Date:  2009-12-16       Impact factor: 9.941

4.  Prognostic impact of cancer/testis antigen expression in advanced stage multiple myeloma patients.

Authors:  Valéria C C Andrade; André L Vettore; Roberta S Felix; Manuella S S Almeida; Fabrício Carvalho; José Salvador R Oliveira; Maria Lourdes Lopes Ferrari Chauffaille; Adagmar Andriolo; Otavia L Caballero; Marco Antonio Zago; Gisele W B Colleoni
Journal:  Cancer Immun       Date:  2008-02-01

5.  The Tumor Antigen NY-ESO-1 Mediates Direct Recognition of Melanoma Cells by CD4+ T Cells after Intercellular Antigen Transfer.

Authors:  Jean Francois Fonteneau; Fabienne Brilot; Christian Münz; Monique Gannagé
Journal:  J Immunol       Date:  2015-11-25       Impact factor: 5.422

Review 6.  Targeting cancer testis antigens in synovial sarcoma.

Authors:  Geoffrey Mitchell; Seth M Pollack; Michael J Wagner
Journal:  J Immunother Cancer       Date:  2021-06       Impact factor: 13.751

7.  Targeting MAGE-C1/CT7 expression increases cell sensitivity to the proteasome inhibitor bortezomib in multiple myeloma cell lines.

Authors:  Fabricio de Carvalho; Erico T Costa; Anamaria A Camargo; Juliana C Gregorio; Cibele Masotti; Valeria C C Andrade; Bryan E Strauss; Otavia L Caballero; Djordje Atanackovic; Gisele W B Colleoni
Journal:  PLoS One       Date:  2011-11-16       Impact factor: 3.240

8.  Coordinated activation of candidate proto-oncogenes and cancer testes antigens via promoter demethylation in head and neck cancer and lung cancer.

Authors:  Ian M Smith; Chad A Glazer; Suhail K Mithani; Michael F Ochs; Wenyue Sun; Sheetal Bhan; Alexander Vostrov; Ziedulla Abdullaev; Victor Lobanenkov; Andrew Gray; Chunyan Liu; Steven S Chang; Kimberly L Ostrow; William H Westra; Shahnaz Begum; Mousumi Dhara; Joseph Califano
Journal:  PLoS One       Date:  2009-03-23       Impact factor: 3.240

Review 9.  Evolution of Cancer Vaccines-Challenges, Achievements, and Future Directions.

Authors:  Ban Qi Tay; Quentin Wright; Rahul Ladwa; Christopher Perry; Graham Leggatt; Fiona Simpson; James W Wells; Benedict J Panizza; Ian H Frazer; Jazmina L G Cruz
Journal:  Vaccines (Basel)       Date:  2021-05-20

10.  Cancer-testis antigen expression and immunogenicity in AL amyloidosis.

Authors:  M A Rosenzweig; H Landau; D Seldin; C O'Hara; S Girnius; N Hanson; D Frosina; C Sedrak; M Arcila; R L Comenzo; S Giralt; S Gnjatic; A A Jungbluth; G Koehne
Journal:  Blood Cancer J       Date:  2012-09-14       Impact factor: 11.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.